交界性卵巢肿瘤患者卵巢组织移植的安全性
该前瞻性实验研究对11例因交界性卵巢肿瘤(BOT)冻存卵巢组织的患者进行冻融组织及免疫缺陷小鼠异种移植分析,组织学、免疫组化(MUC1、CK7)和RT-qPCR显示10例冻融组织阴性;异种移植中9例无恶性细胞,2例移植物检出腺体病变,其中1例确认为BOT、另1例表达子宫内膜异位症标志物CD10。
要点
- 11例BOT患者冻融卵巢组织中10例经组织学、免疫组化和RT-qPCR分析为阴性。
- 异种移植后9例无恶性细胞,2例移植物检出腺体病变,其中1例确认为BOT。
- 另1例腺体病变的移植物免疫组化显示子宫内膜异位症标志物CD10表达。
核心结论
- 在11例BOT患者中,1例的冻融及异种移植卵巢组织中发现BOT细胞。
- BOT患者冻存卵巢组织中可存在BOT细胞,因此移植前分析是绝对前提。
- 冻存卵巢组织中也可检出子宫内膜异位症,此种情形也应谨慎。
研究设计与样本
- 前瞻性实验研究,在学术研究单位进行,使用11例因BOT冻存卵巢组织的患者的卵巢组织。
- 对11例患者的冻融卵巢组织进行组织学、MUC1和CK7免疫组化及CK7和MUC1的RT-qPCR分子分析。
- 将卵巢组织在免疫缺陷小鼠中异种移植5个月,对移植物进行组织学、免疫组化和RT-qPCR分析,并对选定样本进行CD10免疫组化。
主要发现
- 组织学、免疫组化和RT-qPCR分析显示11份卵巢组织样本中10份为阴性。
- 异种移植样本分析显示9份无恶性细胞,但2份移植物经组织学检出腺体病变。
- 这2份移植物中,免疫组化显示CK7和MUC1标志物,RT-qPCR也显示CK7表达。
- 原卵巢组织阳性的那例异种移植中确认BOT,另一例免疫组化显示子宫内膜异位症标志物CD10表达。
临床怎么用
- 作者认为,BOT患者冻存卵巢组织中可发现BOT细胞,因此移植前分析是绝对前提。
- 作者认为,冻存卵巢组织中也可检出子宫内膜异位症,此种情形也应谨慎。
局限性
- 冻存卵巢碎片在移植前无法全部检测,因此移植前分析不能保证所有冻存碎片均无BOT细胞。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Is transplantation of cryopreserved ovarian tissue from patients with borderline ovarian tumors (BOTs) a safe procedure? SUMMARY ANSWER: BOT cells were found in frozen-thawed and xenografted ovarian tissue in 1 of 11 BOT patients. WHAT IS KNOWN ALREADY: The risk of reintroducing malignant cells upon ovarian tissue transplantation has been subject of debate for many years. Reimplantation of cryopreserved ovarian tissue from leukemia patients is unsafe, while results from studies of cryopreserved ovarian tissue from other forms of cancer, such as Hodgkin's lymphoma, are reassuring. STUDY DESIGN, SIZE, DURATION: Prospective experimental study conducted in an academic research unit using ovarian tissue from 11 patients undergoing cryopreservation for BOTs. PARTICIPANTS/MATERIALS, SETTING, METHODS: Histology, immunohistochemistry (IHC) for mucin 1 (MUC1) and cytokeratin 7 (CK7) and molecular analysis by reverse transcription quantitative polymerase chain reaction (RT-qPCR) for CK7 and MUC1 were performed on frozen-thawed ovarian tissue from 11 patients. Long-term (5 months) xenografting of ovarian tissue in immunodeficient mice was performed. The xenografts were analyzed by histology, IHC and RT-qPCR, furthermore IHC for CD10, a marker of endometriosis, was performed on a selected sample. MAIN RESULTS AND THE ROLE OF CHANCE: Analysis by histology, IHC and RT-qPCR indicated 10 of the ovarian tissue samples were negative. Analysis of the xenograft samples indicated nine were negative for malignant cells but in two xenografts glandular lesions were detected by histology. In these two xenografts, CK7 and MUC1 markers were demonstrated by IHC and CK7 expression also by RT-qPCR. A BOT was confirmed in the xenograft in which the original ovarian tissue was positive, while in the other case IHC demonstrated expression of endometriosis marker CD10. LIMITATIONS, REASONS FOR CAUTION: Cryopreserved ovarian fragments cannot be tested before transplantation, therefore the preimplantation analysis cannot guarantee that all cryopreserved fragments will be free of BOT cells. WIDER IMPLICATIONS OF THE FINDINGS: BOT cells can be found in cryopreserved ovarian tissue from BOT patients, therefore preimplantation analysis is an absolute prerequisite. Endometriosis can also be detected in cryopreserved ovarian tissue and caution should also be exercised in this scenario. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by grants from the Fonds National de la Recherche Scientifique de Belgique (FNRS-PDR Convention T.0077.14, Télévie Grant 7.4590.16 awarded to Rossella Masciangelo, and Grant 5/4/150/5 awarded to Marie-Madeleine Dolmans), the Fonds Speciaux de Recherche, and the Foundation Against Cancer. None of the authors have any conflicting interests to declare.
引用
- Masciangelo R, Bosisio C, Donnez J, et al. Safety of ovarian tissue transplantation in patients with borderline ovarian tumors. Hum Reprod. 2018. PMID: 29281007. doi:10.1093/humrep/dex352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。